TY - JOUR
T1 - Comparison of lung cancer aggressiveness in patients who never smoked compared to those who smoked
AU - for the IELCART Investigators
AU - Adler, Shoshana
AU - Yip, Rowena
AU - Chan, Huiwen
AU - Cai, Qiang
AU - Zhu, Yeqing
AU - Triphuridet, Natthaya
AU - Kaufman, Andrew
AU - Taioli, Emanuela
AU - Flores, Raja
AU - Henschke, Claudia I.
AU - Yankelevitz, David F.
N1 - Funding Information:
Funding: This work was partly supported by the Simons Foundation International, Ltd . The sponsor has no involvement in the study design, data collection, analysis and interpretation, writing or the decision to submit for publication.
Funding Information:
Funding: This work was partly supported by the Simons Foundation International, Ltd. The sponsor has no involvement in the study design, data collection, analysis and interpretation, writing or the decision to submit for publication. Potential Conflicts of Interest:, Dr. David Yankelevitz is a named inventor on a number of patents and patent applications related to the evaluation of chest diseases including measurements of chest nodules. Dr. Yankelevitz has received financial compensation for the licensing of these patents. In addition, he is a consultant and co-owner of Accumetra, a private company developing tools to improve the quality of CT imaging and is on the medical advisory board of Carestream, a company that develops radiography equipment and has consulted for Genentech, AstraZeneca and Pfizer. Dr. Henschke is also an inventor of the patents and pending patents owned by Cornell Research Foundation (CRF). As of April 2009, she has divested herself of all royalties and other interests arising from these. Others: None
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/9
Y1 - 2022/9
N2 - Objectives: To determine whether radiographic measures of tumor aggressiveness differ by smoking status. Materials and Methods: All patients diagnosed with non-small-cell lung cancer(NSCLC) ≤ 30 mm in maximum diameter, without clinical evidence of metastasis who had both pre-treatment PET scans and two CT scans at least 90 days apart in a prospective cohort, the Initiative for Early Lung Cancer Research on Treatment(IELCART) at Mount Sinai between 2016 and 2020 were identified. Comparison of two measures of tumor aggressiveness, positron emission tomography(PET) SUVmax and tumor volume doubling time(VDT) by smoking status was performed. Results: Of 417 patients identified, 158 patients had pre-treatment PET scans and at least two CT scans available. The two measures of tumor aggressiveness, SUVmax and VDT values were significantly different between patients who had never smoked and those who smoked: patients who never smoked had lower median SUVmax[2.5(IQR: 1.1–4.8) vs. 4.2(IQR:2.1–9.2),p = 0.002] and longer median VDT[(372.6 days vs. 225.6 days,p = 0.001)] compared to those who smoked. Using multivariable analyses, when adjusting for age and sex alone, SUVmax(p = 0.004) and VDT(p = 0.0001) remained significantly different by smoking status. The final multivariable analysis, adjusted for all three co-variates(sex, age and tumor histology) showed no significant difference in SUVmax and VDT by smoking status [SUVmax(p = 0.25) and VDT(p = 0.06)]. Conclusion: Smoking history does not influence VDT or PET SUVmax measures of lung cancer aggressiveness.
AB - Objectives: To determine whether radiographic measures of tumor aggressiveness differ by smoking status. Materials and Methods: All patients diagnosed with non-small-cell lung cancer(NSCLC) ≤ 30 mm in maximum diameter, without clinical evidence of metastasis who had both pre-treatment PET scans and two CT scans at least 90 days apart in a prospective cohort, the Initiative for Early Lung Cancer Research on Treatment(IELCART) at Mount Sinai between 2016 and 2020 were identified. Comparison of two measures of tumor aggressiveness, positron emission tomography(PET) SUVmax and tumor volume doubling time(VDT) by smoking status was performed. Results: Of 417 patients identified, 158 patients had pre-treatment PET scans and at least two CT scans available. The two measures of tumor aggressiveness, SUVmax and VDT values were significantly different between patients who had never smoked and those who smoked: patients who never smoked had lower median SUVmax[2.5(IQR: 1.1–4.8) vs. 4.2(IQR:2.1–9.2),p = 0.002] and longer median VDT[(372.6 days vs. 225.6 days,p = 0.001)] compared to those who smoked. Using multivariable analyses, when adjusting for age and sex alone, SUVmax(p = 0.004) and VDT(p = 0.0001) remained significantly different by smoking status. The final multivariable analysis, adjusted for all three co-variates(sex, age and tumor histology) showed no significant difference in SUVmax and VDT by smoking status [SUVmax(p = 0.25) and VDT(p = 0.06)]. Conclusion: Smoking history does not influence VDT or PET SUVmax measures of lung cancer aggressiveness.
KW - Computed tomography
KW - Early detection of cancer
KW - Lung neoplasms
KW - Secondhand tobacco smoke exposure
KW - Tumor aggressiveness
UR - http://www.scopus.com/inward/record.url?scp=85135398816&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2022.07.002
DO - 10.1016/j.lungcan.2022.07.002
M3 - Article
AN - SCOPUS:85135398816
SN - 0169-5002
VL - 171
SP - 90
EP - 96
JO - Lung Cancer
JF - Lung Cancer
ER -